In this article, we will discuss Niraparib (1). So, let’s get started.
Niraparib is a medication classified as a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP inhibitors are a class of drugs that interfere with the repair of DNA in cells, particularly in cancer cells. Niraparib is primarily used in the treatment of certain types of cancer.
Indications:
Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
It is also used in patients with advanced ovarian cancer who have received three or more prior chemotherapy regimens.
Mechanism of Action:
PARP inhibitors, including niraparib, work by inhibiting the enzyme PARP. PARP is involved in the repair of damaged DNA in cells. By inhibiting PARP, these drugs prevent cancer cells from repairing their DNA, leading to cell death.
Maintenance Treatment:
Niraparib is commonly used as maintenance therapy. After the initial treatment with platinum-based chemotherapy, it is administered to help prevent or delay the recurrence of ovarian cancer.
Brands:
Niraparib is available under the brand name Zejula.
Administration:
It is an oral medication, usually taken once daily.